Interferons in relapsing remitting multiple sclerosis.

Interferons in relapsing remitting multiple sclerosis.

Detalles Bibliográficos
Autor principal:	Goodin, D
Formato:	Journal article
Lenguaje:	English
Publicado:	2003

Ejemplares similares

Interferons in relapsing remitting multiple sclerosis - Authors' reply
por: Filippini, G, et al.
Publicado: (2003)

Interferons in relapsing remitting multiple sclerosis - Authors' reply
por: Filippini, G, et al.
Publicado: (2003)

Interferons in relapsing remitting multiple sclerosis: a systematic review.
por: Filippini, G, et al.
Publicado: (2003)

Interferon-beta for relapsing-remitting multiple sclerosis: a systematic review
por: Dian HE, et al.
Publicado: (2014-09-01)

Erratum to Interferon-beta for relapsing-remitting multiple sclerosis: a systematic review
por: Dian HE
Publicado: (2015-01-01)

Approved Beta Interferons in Relapsing-Remitting Multiple Sclerosis: is there a one odd out?
por: Alexis Clapin
Publicado: (2012-09-01)

Response to treatment with Interferon beta-1a in patients with relapsing-remitting multiple sclerosis
por: Làzaro Aurelio Vàzquez Gòmez, et al.
Publicado: (2022-10-01)

Thalamic neurodegeneration in relapsing-remitting multiple sclerosis.
por: Wylezinska, M, et al.
Publicado: (2003)

Thalamic neurodegeneration in relapsing: Remitting multiple sclerosis
por: Cifelli, A, et al.
Publicado: (2003)

Comorbidity in in patients with relapsing-remitting multiple sclerosis
por: O.V. Somilo, et al.
Publicado: (2024-10-01)

Fingolimod for the Treatment of Relapsing-Remitting Multiple Sclerosis
por: Burcu Altunrende, et al.
Publicado: (2017-12-01)

Advances in the treatment of relapsing - Remitting multiple sclerosis
por: Radu Tanasescu, et al.
Publicado: (2014-04-01)

Postural Control in Relapsing-Remitting Multiple Sclerosis
por: Flavia Salvaterra Cusin, et al.
Publicado: (2022-10-01)

Multiple Sclerosis Relapsing Remitting Progressive Type
por: Nora Fitri, et al.
Publicado: (2020-12-01)

Direct costs of relapses in patients with relapsing-remitting multiple sclerosis
por: V. Casado, et al.
Publicado: (2021-07-01)

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis.
por: Petkau, A, et al.
Publicado: (2004)

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis
por: Petkau, A, et al.
Publicado: (2004)

Cost-utility analysis of interferon beta-1a (Avonex and Cinnovex) for relapsing remitting multiple sclerosis
por: Rahil Sadat Shahtaheri, et al.
Publicado: (2018-06-01)

Experience with the long-term use of interferons β in the treatment of relapsing-remitting multiple sclerosis. Case report
por: Taras O. Simaniv, et al.
Publicado: (2024-12-01)

Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis
por: Fernando Rodríguez-Jorge, et al.
Publicado: (2024-11-01)

Oxidative stress in relapsing-remitting multiple sclerosis patients
por: Samaneh Sabouri, et al.
Publicado: (2023-09-01)

Effectiveness of Copaxone in patients with relapsing-remitting multiple sclerosis
por: V. M. Alifirova, et al.
Publicado: (2010-08-01)

Subcutaneous Ofatumumab in Patients with Relapsing-remitting Multiple Sclerosis
por: Halil Önder
Publicado: (2019-06-01)

Serum prolactin in patients with relapsing remitting multiple sclerosis
por: Hoda A. Alwakil, et al.
Publicado: (2020-07-01)

Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
por: Burgal María, et al.
Publicado: (2010-04-01)

Mild cognitive impairment in relapsing-remitting multiple sclerosis
por: Dimakopoulou Aikaterini, et al.
Publicado: (2008-04-01)

The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy.
por: Damiano Paolicelli, et al.
Publicado: (2016-01-01)

Profiling of Canonical and Non-Traditional Cytokine Levels in Interferon-β-Treated Relapsing–Remitting-Multiple Sclerosis Patients
por: Chiara D’Angelo, et al.
Publicado: (2018-06-01)

Cerebellar information processing in relapsing-remitting multiple sclerosis (RRMS).
por: Lesage, E, et al.
Publicado: (2010)

Cerebellar Information Processing in Relapsing-Remitting Multiple Sclerosis (RRMS)
por: E. Lesage, et al.
Publicado: (2010-01-01)

Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
por: Lugaresi A, et al.
Publicado: (2013-06-01)

Management of relapsing-remitting multiple sclerosis: diagnosis and treatment guidelines
por: Paty, D, et al.
Publicado: (1999)

Subtypes of relapsing-remitting multiple sclerosis identified by network analysis
por: Quentin Howlett-Prieto, et al.
Publicado: (2023-01-01)

Altered Serum Cytokine Profiles in Relapse Phase of Relapsing-Remitting Multiple Sclerosis
por: Forooz Peiravian, et al.
Publicado: (2016-09-01)

Corrigendum: Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis
por: Fernando Rodríguez-Jorge, et al.
Publicado: (2024-12-01)

Prooxidant-antioxidant balance in relapsing-remitting multiple sclerosis patients
por: Samaneh Sabouri, et al.
Publicado: (2023-07-01)

Hopelessness in Patients with Early-Stage Relapsing-Remitting Multiple Sclerosis
por: Sainz de la Maza S, et al.
Publicado: (2023-06-01)

Dimethyl fumarate in the treatment of relapsing–remitting multiple sclerosis: an overview
por: Roberto Bomprezzi
Publicado: (2015-01-01)

Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis
por: Romme Christensen Jeppe, et al.
Publicado: (2012-09-01)

Systematic review of prediction models in relapsing remitting multiple sclerosis.
por: Fraser S Brown, et al.
Publicado: (2020-01-01)